Wolverine peptide pen ingredients must be checked on the exact product listing. Wolverine is a nickname, not a standard formulation. An earlier version of this article used it for BPC-157 and TB-500, while the current Svelta Labs Wolverine Recovery Pen lists a different blend.

What the current Svelta Wolverine listing says

The Wolverine Recovery Pen product page identifies CJC-1295 no DAC and Ipamorelin. That is the catalogue identity to use when referring to this Svelta product. The commercial name should not be used to infer BPC-157, TB-500 or a particular quantity of any ingredient.

For terminology, the library has separate profiles for CJC-1295 no DAC and Ipamorelin. These profiles are research context, not evidence of a clinical result from the combined pen.

Where BPC-157 and TB-500 fit in this discussion

The earlier Wolverine-stack discussion concerned BPC-157 and TB-500 and their association with tissue-repair research. It should not be mistaken for a description of the current product. Claims of rapid healing or regeneration require more than an evocative nickname or a laboratory mechanism.

TB-500 identity also needs care: the FDA identifies a thymosin beta-4 fragment under that name. It should not automatically be described as identical to full-length thymosin beta-4 or assigned the findings of a differently specified substance.

Keep research evidence and sourcing claims separate

For a study to support a claim about a product, the material, formulation, route and outcome need to be relevant. A supplier's statement about quality is not an independent assay, and neither a purity figure nor a research-use label establishes suitability for human consumption.

  • Read the listed ingredients rather than guessing from the product name.
  • Check that supporting documentation refers to the same compound and batch.
  • Separate a finding about one ingredient from evidence about a blend.
  • Do not use this comparison as an injury-treatment or dosing recommendation.

Sources: current Svelta Wolverine Recovery Pen catalogue record and FDA compounding safety information. For broader guidance, read how to read a research product page or visit Svelta Labs.

Sources

FDA compounding safety information: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks